Rifaximin: all 149 studies that test it

Page 1 of 2. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• SIMBA in Irritable Bowel Syndrome (IBS)Not yet recruitingNCT07882953Phase 1
• Rifaximin Treatment in Bloating Predominant Functional Bowel DisordersNot yet recruitingNCT07522255Phase 3
• Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute DiarrheaRecruitingNCT07285785Phase 4
• Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined SignificanceRecruitingNCT07209371Phase 2
• Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on TicagrelorNot yet recruitingNCT07203846Phase 4
• Efficacy and Safety of Rifaximin in Treating MAFLDRecruitingNCT07185932Early Phase 1
• Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon SurgeryNot yet recruitingNCT07180615Phase 4
• Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)Not yet recruitingNCT06808009Not applicable
• Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer PatientsNot yet recruitingNCT06783153Phase 1/2
• Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.RecruitingNCT06772064Not applicable
• Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver TransplantRecruitingNCT06743464Not applicable
• Efficacy of Rifaximin With NAC in IBS-DRecruitingNCT06727422Phase 2
• Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection FractionRecruitingNCT06652087Not applicable
• BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HERecruitingNCT06538077Phase 4
• Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal DistensionNot yet recruitingNCT06518850Phase 1/2
• Rifaximin for the Secondary Prevention of Recurrent PouchitisRecruitingNCT06312683Phase 4
• Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)Not yet recruitingNCT06199843Not applicable
• Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute LeukemiaRecruitingNCT06058572Phase 2
• The Efficacy and Safety of Rifaximin TreatmentRecruitingNCT05786859Early Phase 1
• Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide AdjunctRecruitingNCT05677282Phase 4
• Effects of Rifaximin on Gut Microbiota and EmotionRecruitingNCT05587036Phase 2/3
• Rifaximin Therapy vs Low FODMAP Diet In IBSRecruitingNCT04841980Phase 4
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and LactuloseRecruitingNCT04073290Phase 4
• Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic ColitisRecruitingNCT04043897Phase 2
• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular RosaceaCompletedNCT05150587Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseCompletedNCT05098028Phase 2Results posted
• Rifaximin in Patients With Diabetic GastroparesisTerminatedNCT04254549Phase 2Results posted
• Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerTerminatedNCT04249622Phase 2Results posted
• Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired SubjectsTerminatedNCT03818672Phase 4Results posted
• Rifaximin on Visceral HypersensitivityTerminatedNCT03462966Phase 2Results posted
• A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath TestingCompletedNCT03219528Phase 4Results posted
• Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori InfectionCompletedNCT03124199Phase 3Results posted
• A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.TerminatedNCT02920242Phase 3Results posted
• Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's DiarrheaCompletedNCT02498418Phase 3Results posted
• Treating Bacterial Overgrowth in Parkinson's DiseaseCompletedNCT02470780Phase 2/3Results posted
• Rifaximin Therapy in Chronic Kidney DiseaseCompletedNCT02342639Phase 4Results posted
• Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic EncephalopathyCompletedNCT02163837Not applicableResults posted
• Rifaximin for Chronic Immune Activation in People With HIVCompletedNCT01866826Phase 1/2Results posted
• Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic EncephalopathyTerminatedNCT01846663Phase 4Results posted
• Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthCompletedNCT01662791Phase 3Results posted
• Role of Methane in Glycemic ControlCompletedNCT01638429Early Phase 1Results posted
• Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment StudyCompletedNCT01543178Phase 3Results posted
• A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT ScansCompletedNCT01542541Not applicableResults posted
• Rifaximin as a Modulator of Microbial Translocation and Immune ActivationCompletedNCT01466595Phase 2Results posted
• Rifaximin in Fatty Liver DiseaseTerminatedNCT01355575Phase 4Results posted
• Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal CancerCompletedNCT01345175Phase 3Results posted
• Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac DiseaseCompletedNCT01137955Not applicableResults posted
• Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel SyndromeCompletedNCT00945334Not applicableResults posted
• Trial of Rifaximin in the Treatment of Tropical EnteropathyCompletedNCT00858988Not applicableResults posted
• Rifaximin for Prevention of Travellers' DiarrheaCompletedNCT00742469Phase 3Results posted
• Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)CompletedNCT00731679Phase 3Results posted
• Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)CompletedNCT00724126Phase 3Results posted
• Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic EncephalopathyCompletedNCT00686920Phase 3Results posted
• Gulf War Digestive Health StudyCompletedNCT00680836Not applicableResults posted
• Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?CompletedNCT00619970Not applicableResults posted
• Transit Time and Bacterial Overgrowth Using SmartPill CapsuleTerminatedNCT00577772Not applicableResults posted
• Rifaximin in Minimal Hepatic EncephalopathyCompletedNCT00533910Not applicableResults posted
• RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled TrialTerminatedNCT00364689Phase 3Results posted
• A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic EncephalopathyCompletedNCT00298038Phase 3Results posted
• A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedNCT00269399Phase 3Results posted
• Effect of Rifaximin on Thrombocytopenia in Patients With HCV-Related Liver CirrhosisCompletedNCT07791940Phase 4
• A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.CompletedNCT07037394Phase 4
• Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic IndexesTerminatedNCT06630572Phase 4
• Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With CiprofloxacinCompletedNCT06234046Phase 3
• The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With RifaximinCompletedNCT06223685Not applicable
• Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic PatientsCompletedNCT05621005Phase 2
• Rifaximin for Treatment of Bloating in Children and Adults With Cystic FibrosisWithdrawnNCT05408910Phase 2/3
• Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy VolunteersCompletedNCT05159427Phase 1
• Primary Prophylaxis for Spontaneous Bacterial PeritonitisTerminatedNCT04775329Phase 2/3
• Microbial Resistance of Rifaximin in Hepatic EncephalopathyCompletedNCT04736836Phase 4
• Weight Loss Benefits of Rifaximin in an Intermittent Fasting DietStatus unknownNCT04674176Phase 4
• Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its TreatmentStatus unknownNCT04302402Phase 2
• Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal DysmotilityWithdrawnNCT04244877Phase 3
• Rifaximin Versus Norfloxacin in Spontaneous Bacterial PeritonitisStatus unknownNCT04159870Phase 3
• Autologous Transplant Targeted Against Crohn'sWithdrawnNCT04154735Phase 2
• Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialStatus unknownNCT04118699Phase 2
• Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-DStatus unknownNCT04074421Phase 4
• Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin UsersStatus unknownNCT03962283Phase 2/3
• Modulation of Gut Microbiota by Rifaximin in PD PatientsStatus unknownNCT03958708Phase 1/2
• Rifaximin in Patients With Monoclonal GammopathyCompletedNCT03820817Phase 1
• Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF DevelopmentCompletedNCT03780673Phase 2/3
• Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 DiabetesStatus unknownNCT03758144Not applicable
• Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant DiarrheaCompletedNCT03729271Phase 4
• Rifaximin to Modify the Disease Course in Sickle Cell DiseaseStatus unknownNCT03719729Phase 2
• Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated CirrhosisCompletedNCT03695705Phase 3
• Rifaximin-treatment of Collagenous ColitisStatus unknownNCT03658993Phase 3
• The Effect of Rifaximin on Portal Vein ThrombosisStatus unknownNCT03631147Not applicable
• Microbiota Intervention to Change the Response of Parkinson's DiseaseSuspendedNCT03575195Phase 1/2
• Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel SyndromeCompletedNCT03557788Phase 4
• Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell TransplantationCompletedNCT03529825Early Phase 1
• Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's DiseaseStatus unknownNCT03185624Phase 3
• Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's DiseaseStatus unknownNCT03185611Phase 3
• Simvastatin Plus Rifaximin in Decompensated CirrhosisCompletedNCT03150459Phase 2
• Low-dose Rifaximin in the Treatment of Covert Hepatic EncephalopathyCompletedNCT03077217Phase 4
• Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With AscitesCompletedNCT03069131Phase 3
• Rifaximin in Patients With Gastroesophageal Variceal BleedingCompletedNCT02991612Not applicable
• Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal BleedingStatus unknownNCT02964195Not applicable
• Metabolic Consequences of Gastrointestinal SurgeryTerminatedNCT02836353Not applicable
• Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal DiseaseWithdrawnNCT02738905Early Phase 1
• Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant DiarrheaStatus unknownNCT02651740Phase 2/3

← Rifaximin overview